標(biāo)題：福雷蘆單抗，Foralumab，CAS: 946415-64-1，AntibodySystem Laboratories

貨號(hào)：DHC27705

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75403.html

別名：NI-0401, CAS: 946415-64-1

簡(jiǎn)介：Foralumab (NI-0401) 是一種口服有效的人源化單克隆抗體，靶向 CD3。Foralumab 可調(diào)節(jié) NSG 小鼠中由人類造血干細(xì)胞重建的人類細(xì)胞的免疫反應(yīng)。

貨號(hào)：DHC27705

產(chǎn)品品牌：Antibodysystem

通用名：Foralumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：NI-0401

靶點(diǎn);物種：Human CD3E

種類：Homo sapiens

受體鑒定：IgG1-kappa

CAS: 946415-64-1

存儲(chǔ)條件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻(xiàn)：

Targeting T cells in inflammatory bowel disease. PMID: 32585338
Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. PMID: 27161438
Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study. PMID: 34475873
Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study. PMID: 35095916
Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice. PMID: 28739191
Nasal administration of anti-CD3 mAb (Foralumab) downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells in subjects with COVID-19. PMID: 36881624
Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects. PMID: 36505477
Flow Characteristics of the Conjugate of Anti-CD3 Monoclonal Antibodies and Magnetic Nanoparticle in PBS and Blood Vessels. PMID: 36527662
Injection Effect of Anti-CD3 Monoclonal Antibody on Primo Vessel in Lymph Vessel of Rabbit with Lipopolysaccharide-Induced Inflammation. PMID: 35770572
Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases. PMID: 23254986
Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH. PMID: 29920654
Preclinical efficacy of humanized, non-FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia. PMID: 32483610